Antibody protecting from bscb leakage induced cns damages

The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

Keywords: Ischemic stroke - Hemorrhagic stroke - Neurodegenerative diseases - Multiple Sclerosis - ,
Patent Application number: EP N°13 002 641.2
Inventors:
Richard MACREZ Fabian DOCAGNE Denis VIVIEN Karl-Uwe PETERSEN
Publications:
Brain. 2016 Sep;139(Pt 9):2406-19. doi: 10.1093/brain/aww172. Epub 2016 Jul 19 Neuropharmacology. 2013 Apr;67:267-71. doi: 10.1016/j.neuropharm.2012.11.023. Epub 2012 Dec 3. Stroke. 2011 Aug;42(8):2315-22. doi: 10.1161/STROKEAHA.110.606293. Epub 2011 Jun 16. J Neurochem. 2010 Apr;113(2):447-53. doi: 10.1111/j.1471-4159.2010.06598.x. Epub 2010 Jan 18.

Reference:

BIO13193-T2

Business Developper
contact
Grégoire SERRA
Grégoire SERRA
Business Developer
Patent filling date: 2013-05-21

You might also be interested in